| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
32 |
S1 |
p. vii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
32 |
S1 |
p. i
|
artikel
|
| 3 |
Journal Information
|
|
|
|
32 |
S1 |
p. ii
|
artikel
|
| 4 |
8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
|
Moreno, V.
|
|
|
32 |
S1 |
p. S5
|
artikel
|
| 5 |
37MO Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer
|
Sen, T.
|
|
|
32 |
S1 |
p. S16
|
artikel
|
| 6 |
35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers
|
Dardenne, E.
|
|
|
32 |
S1 |
p. S15
|
artikel
|
| 7 |
38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
|
Mates, M.
|
|
|
32 |
S1 |
p. S16
|
artikel
|
| 8 |
34MO Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials
|
Pobel, C.J.
|
|
|
32 |
S1 |
p. S14-S15
|
artikel
|
| 9 |
36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
|
Sacher, A.
|
|
|
32 |
S1 |
p. S15
|
artikel
|
| 10 |
33O A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, in patients (pts) with advanced solid tumours
|
Wei, X-L.
|
|
|
32 |
S1 |
p. S14
|
artikel
|
| 11 |
32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)
|
Chen, H-J.
|
|
|
32 |
S1 |
p. S14
|
artikel
|
| 12 |
19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions
|
Hamid, O.
|
|
|
32 |
S1 |
p. S9
|
artikel
|
| 13 |
7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
|
Hollebecque, A.
|
|
|
32 |
S1 |
p. S4
|
artikel
|
| 14 |
5P Anti-GD2 chimeric antigen receptor & TRAIL modified mesenchymal progenitors as novel strategy against Ewing’s sarcoma
|
Golinelli, G.
|
|
|
32 |
S1 |
p. S2
|
artikel
|
| 15 |
45P Antimetastatic activity of apigenin in human breast carcinoma cells by regulation of different MMPs gene expression
|
Rajoriya, S.
|
|
|
32 |
S1 |
p. S18
|
artikel
|
| 16 |
15P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results
|
Di Liello, R.
|
|
|
32 |
S1 |
p. S7
|
artikel
|
| 17 |
6P AsiDNA targets drug-tolerant persister cells responsible of resistance to PARP inhibitors
|
Jdey, W.
|
|
|
32 |
S1 |
p. S3
|
artikel
|
| 18 |
17P BCL6 and Notch pathway: A signaling axis leading to a novel druggable biotarget in triple-negative breast cancer
|
De Santis, F.
|
|
|
32 |
S1 |
p. S8
|
artikel
|
| 19 |
11P Convoluted role of H19 long non-coding RNA in regulating ICAM-1 and PVR in breast cancer patients
|
Elkhouly, A.
|
|
|
32 |
S1 |
p. S6
|
artikel
|
| 20 |
3P Determination of therapeutic effects of multifunctional micelle-based nanocarriers on breast cancer cells
|
Ulu, G.T.
|
|
|
32 |
S1 |
p. S1
|
artikel
|
| 21 |
12P DNMT1/3-targeting microRNAs are over-expressed in the exosomes of estrogen-resistant breast cancer cells
|
Sorokin, D.V.
|
|
|
32 |
S1 |
p. S6
|
artikel
|
| 22 |
39P Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)
|
Tsimafeyeu, I.
|
|
|
32 |
S1 |
p. S16-S17
|
artikel
|
| 23 |
10P Emerging role of Telomeric repeat-containing RNA TERRA in hepatocellular carcinoma
|
Manganelli, M.
|
|
|
32 |
S1 |
p. S6
|
artikel
|
| 24 |
46P ERα heterogeneous expression and the TGF-βRI status in the tumour predicted tamoxifen resistance
|
Babyshkina, N.
|
|
|
32 |
S1 |
p. S18-S19
|
artikel
|
| 25 |
47P Evaluation of combinations of photoswitchable novel combretastatin A-4 analogues with chemotherapy drugs and metformin
|
Scherbakov, A.M.
|
|
|
32 |
S1 |
p. S19
|
artikel
|
| 26 |
28P Hijacking CCAT1/miR-17-5p axis alleviates immune checkpoint blockers resistance in PDL1+ TNBC patients
|
Selem, N.
|
|
|
32 |
S1 |
p. S12
|
artikel
|
| 27 |
16P How to translate what we learned from Gaucher’s disease into new treatments for brain tumours
|
Paret, C.
|
|
|
32 |
S1 |
p. S7
|
artikel
|
| 28 |
20P IGN002 (antiCD20-IFNα2b) intravenously administered tumour targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma
|
Lakshmikanthan, S.
|
|
|
32 |
S1 |
p. S9
|
artikel
|
| 29 |
4P Immunohybridoma cell-based vaccine for the treatment of patients with castration-resistant prostate cancer
|
Hawlina, S.
|
|
|
32 |
S1 |
p. S2
|
artikel
|
| 30 |
44P Investigation of scorpion venom-derived anticancer peptides inhibition of metastatic cancer cells growth and induction of apoptosis
|
Tang, Y-Q.
|
|
|
32 |
S1 |
p. S18
|
artikel
|
| 31 |
1P Is 177Lu-PSMA an effective treatment modality for mCRPC patients with visceral metastasis?
|
Gupta, M.
|
|
|
32 |
S1 |
p. S1
|
artikel
|
| 32 |
14P MALAT-1: A novel LncRNA modulating STAT-3 regulated cystathionine-γ-lyase (CSE) in breast cancer
|
Khater, N.
|
|
|
32 |
S1 |
p. S7
|
artikel
|
| 33 |
24P miR-17-5p: A potential activator of natural killer cells through tuning STAT3/H19/ULBP2 axis in breast cancer
|
Zeinelabdeen, Y.
|
|
|
32 |
S1 |
p. S10-S11
|
artikel
|
| 34 |
27P MiR-939-5p exhibits tumour suppressor activity and immune surveillance manipulation in triple-negative breast cancer
|
Nafea, H.M.
|
|
|
32 |
S1 |
p. S11
|
artikel
|
| 35 |
2P Molecular imaging evaluation of a novel Claudin18.2 specific monoclonal antibody labeled with radionuclide
|
Zhu, H.
|
|
|
32 |
S1 |
p. S1
|
artikel
|
| 36 |
18P Mutational landscape of metastatic lung squamous cell carcinoma associated with basal cell hyperplasia
|
Gerashchenko, T.S.
|
|
|
32 |
S1 |
p. S8
|
artikel
|
| 37 |
29P Non-diploidy related prognostic molecular signature (NPMS) predict an “immunologically hot” phenotype in squamous cell lung cancer
|
Hu, Z.
|
|
|
32 |
S1 |
p. S12
|
artikel
|
| 38 |
40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies
|
Ho, J.S.
|
|
|
32 |
S1 |
p. S17
|
artikel
|
| 39 |
21P Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors
|
Vlachostergios, P.J.
|
|
|
32 |
S1 |
p. S9
|
artikel
|
| 40 |
43P Pre-clinical evaluation of potent and orally bioavailable next-generation inhibitors targeting the family of mutants that drive oncogenic BRAF dimer formation
|
Han, Y-C.
|
|
|
32 |
S1 |
p. S18
|
artikel
|
| 41 |
23P Prediction of response to atezolizumab plus nab-paclitaxel in unresectable locally advanced triple-negative breast cancer (TNBC): The clinical usefulness of PD-L1 mRNA expression in plasma-derived exosomes
|
Raimondi, L.
|
|
|
32 |
S1 |
p. S10
|
artikel
|
| 42 |
9P Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials
|
Procureur, A.
|
|
|
32 |
S1 |
p. S5
|
artikel
|
| 43 |
25P Promising immuno-oncological role of rosemary against breast cancer through altering miR-17-5p, MALAT-1, H19 and tumour microenvironment
|
Soliman, R.A.
|
|
|
32 |
S1 |
p. S11
|
artikel
|
| 44 |
30P Protein signature associated with response and progression free survival in late-stage NSCLC patients treated with anti-PD-1 blockade
|
Romano, E.
|
|
|
32 |
S1 |
p. S12
|
artikel
|
| 45 |
31P Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience
|
Patel, G.
|
|
|
32 |
S1 |
p. S12-S13
|
artikel
|
| 46 |
26P Targeted photoimmunotherapy of tumour-specific nanomedicine for targeted triple-negative breast cancer therapy
|
Vellingiri, Y.
|
|
|
32 |
S1 |
p. S11
|
artikel
|
| 47 |
48P Target mining and drug repurposing for hepatocellular carcinoma via bioinformatic and computational approaches
|
Nair, G.
|
|
|
32 |
S1 |
p. S19
|
artikel
|
| 48 |
41P The functional GRHL3-FLG axis predicts targeted therapy response in head and neck cancer
|
Bai, Y.
|
|
|
32 |
S1 |
p. S17
|
artikel
|
| 49 |
13P The role of long non-coding RNA RAMS11 in promoting colorectal cell development and metastasis
|
Islam Khan, M.Z.
|
|
|
32 |
S1 |
p. S6-S7
|
artikel
|
| 50 |
22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis
|
Missri, L.
|
|
|
32 |
S1 |
p. S10
|
artikel
|
| 51 |
42P Using patient-reported outcomes (PROs) in phase I/II dose-finding oncology trials (DPOT): A global survey
|
Lai-Kwon, J.E.
|
|
|
32 |
S1 |
p. S17
|
artikel
|
| 52 |
Society Pages
|
|
|
|
32 |
S1 |
p. v-vi
|
artikel
|
| 53 |
Table of Contents
|
|
|
|
32 |
S1 |
p. iv
|
artikel
|
| 54 |
Title Page
|
|
|
|
32 |
S1 |
p. iii
|
artikel
|
Tijdschrift beschrijving